Related Experiment Video
Updated: Feb 6, 2026

Bioluminescence Imaging of NADPH Oxidase Activity in Different Animal Models
Published on: October 22, 2012
A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats
Debra Dorotea1, Guideock Kwon1, Jung Hwa Lee1
1Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea.
Background:
NADPH oxidases (Nox) is a major enzyme system contributing to oxidative stress, which plays an important role in the pathogenesis of diabetic kidney disease (DKD). We have shown an elevation of renal Nox1, Nox2, and Nox4 in diabetic mice. APX-115, a pan-Nox inhibitor, attenuated the progression of DKD in mice. As the standard diabetic mice cannot fully mimic human DKD, the present study was aimed to show the dose-dependent effect and to provide a confirmatory evidence of APX-115 in attenuating DKD in diabetic rats.
Method:
Type 1 diabetes was induced by a single 60 mg/kg intraperitoneal injection of streptozotocin in Sprague-Dawley rats. 0.5, 5, or 30 mg APX-115/kg/day or losartan 1 mg/kg/day were administered orally to diabetic rats for 8 weeks.
Results:
APX-115 treatment showed an improvement in kidney function and tubular and podocyte -injury, as well as attenuation of inflammation, fibrosis, and oxidative stress as much as losartan, a comparative drug and mainstay treatment in DKD. Therapeutic effect of APX-115 was exhibited in a dose-dependent manner; a dose of 30 mg/kg displayed a superior efficacy.
Conclusion:
This finding verified the pre-clinical data of APX-115 in protecting against DKD, which is important to bring APX-115 toward the next stage of drug development.
Insights
The novel pan-Nox inhibitor APX-115 effectively treats diabetic kidney disease (DKD) in rats, showing dose-dependent improvements in kidney function and reduced injury. This confirms APX-115
Area of Science:
- Nephrology
- Pharmacology
- Oxidative Stress Research
Background:
- NADPH oxidases (Nox) contribute to oxidative stress in diabetic kidney disease (DKD) pathogenesis.
- Renal Nox1, Nox2, and Nox4 are elevated in diabetic conditions.
- Previous studies indicated APX-115, a pan-Nox inhibitor, attenuates DKD in mice.
Purpose of the Study:
- To investigate the dose-dependent effects of APX-115 in a rat model of DKD.
- To provide confirmatory evidence for APX-115's efficacy in attenuating DKD progression.
Main Methods:
- Type 1 diabetes was induced in Sprague-Dawley rats using streptozotocin.
- Diabetic rats received oral administration of APX-115 (0.5, 5, or 30 mg/kg/day) or losartan (1 mg/kg/day) for 8 weeks.
Main Results:
- APX-115 improved kidney function, reduced tubular and podocyte injury, and attenuated inflammation, fibrosis, and oxidative stress.
- The therapeutic effects of APX-115 were dose-dependent, with 30 mg/kg showing superior efficacy.
- APX-115 demonstrated comparable efficacy to losartan, a standard DKD treatment.
Conclusions:
- APX-115 demonstrates significant protective effects against DKD in a rat model.
- These findings validate pre-clinical data and support advancing APX-115 to further drug development stages.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management

